An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery

Action Pharma A/S0 个研究点目标入组 75 人开始时间: 2010年9月29日最近更新: 2012年3月19日

试验速览

暂无简介。

•1. Has signed the trial-specific informed consent form.
•2. Patients = 18 years old, male or female, not of childbearing potential (postmenopausal or permanently sterilized, e.g. tubal ligation, hysterectomy, bilateral salpingectomy), regardless of ethnicity.
•3. Patients undergoing combined coronary artery bypass grafting (CABG) surgery and surgery of one or more cardiac valve (valve(s) surgery), or
•4. Patients undergoing surgery of more than one cardiac valve (valves surgery), or
•5. Patients undergoing surgery of the aortic root or ascending part of the aorta, or
•6. Patients undergoing surgery of the aortic root or ascending part of the aorta, combined with CABG and/or valve(s) surgery, or
•7. Patients with stage III chronic kidney disease (eGFR 30-59 ml/min determined by the Modification of Diet in Renal Disease (MDRD) undergoing CABG or Single Valve surgery
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Cardiac surgery to be performed off pump” without cardiopulmonary bypass.
•2. Cardiac surgery to be performed with hypothermic circulatory arrest.
•3. Confirmed or suspected endocarditis.
•4. EF = 20%, evaluated within 2 months prior to screening visit.
•5. Requiring a reoperation on one of the valves within 3 months following the original valve surgical procedure.
•6. Active peptic ulcer disease and gastritis.
•7. Receiving dopamine, adrenalin or noradrenalin at any dose at any time 14 days prior to Day of surgery.
•8. Known or suspected hypersensitivity to the investigational medicinal product.
•9. Current participation in any other interventional clinical trial.
•10. Previously dosed with AP214.
•11. Use of investigational medicinal products within the previous 6 months.
•12. Body weight above 130 kg.
•13. History of any organ transplant.
•14. Women who are of childbearing potential, pregnant, or breast-feeding.
•15. Current abuse of alcohol or substance, according to the investigator’s medical judgment.
•16. Has a mental incapacity or language barriers precluding adequate understanding of trial procedures.
•17. Any history of cancer within the last 2 years
•18. Any history of dialysis.
•19. Is considered by the Investigator unsuitable to participate in the trial for any other reason, for instance due to a significant serious underlying condition.

发起方